BRCA2 and hereditary cancer: Considering these changes in genetic testing practices, we re-examined the utility of a clinical history–based approach for classification of BRCA1/BRCA2 VUS in a cohort of >170,000 individuals undergoing hereditary cancer MGPT to develop prediction models that in turn allow inferences to be made about individual variants that can be included in multifactorial classification models.